Ingunn Dybedal

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

Eva Hellström‐Lindberg, Nina Gulbrandsen, Greger Lindberg et al. · British Journal of Haematology · 2003 · 454 citations · Full text

Hematological Malignancy, Immunohematology, Laboratory Hematology +15

Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects

Charlotte Schwab, Annemarie Gabrysch, Peter Olbrich et al. · Journal of Allergy and Clinical Immunology · 2018 · 423 citations · Full text

Clinical Immunology, Allergy, Lymphocyte Development +12

Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo

Petter Woll, Una Kjällquist, Onima Chowdhury et al. · Cancer Cell · 2014 · 318 citations · Full text

Hematological Malignancy, Bone Marrow Failure, Myelodysplastic Syndromes +9

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Satu Mustjoki, Marja Ekblom, T. Petteri Arstila et al. · Leukemia · 2009 · 316 citations

Medicine, Malignant Blood Disorder, Immunology +5

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Eva Hellström-Lindberg, Tomas Ahlgren, Yves Béguin et al. · Blood · 1998 · 306 citations · Full text